Role of neoadjuvant therapy in the management of pancreatic cancer: Is the era of biomarkerdirected therapy here?

Current Oncology

Volumn 21, Issue 4, 2014, Pages

  Tsvetkova, Elena V ^a   Asmis, T R ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Biomarkers; Borderline resectability; Chemoradiation; Neoadjuvant therapy; Pancreatic cancer

Indexed keywords

EID: 84905708493     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.2006     Document Type: Article

References (47)

1. Canadian Cancer Society. Pancreatic Cancer Statistics [Web page]. Toronto, ON: Canadian Cancer Society; 2013. [Available at: http://www.cancer.ca/en/cancer-information/cancer-type/pancreatic/statistics/?region=on; cited February 2, 2014]
2. Conroy T, Desseigne F, Ychou M, et al. on behalf of the Groupe Tumeurs Digestives of Unicancer and the prodige Intergroup. folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25.
3. Von Hoff DD, Ervin TJ, Arena FP, et al. Results of a randomized phase iii trial (mpact) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with pet and CA19-9 correlates [abstract 4005]. J Clin Oncol 2013;31:. [Available online at: http://meetinglibrary.asco.org/content/116827-132; cited June 1, 2014]
4. Canadian Cancer Society's Steering Committee. Canadian Cancer Statistics 2010. Toronto, ON: Canadian Cancer Society; 2010.
5. de Castro SM, Kuhlmann KF, van Heek NT, et al. Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy. J Gastrointest Surg 2004;8:775-84.
6. Rau BM, Moritz K, Schuschan S, Alsfasser G, Prall F, Klar E. R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use. Surgery 2012;152(suppl 1):S103-11.
7. Yekebas EF, Bogoevski D, Cataldegirmen G, et al. En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients. Ann Surg 2008;247:300-9.
8. Merkow RP, Bilimoria KY, Tomlinson JS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg 2013;:[Epub ahead of print].
9. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-79.
10. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Pancreatic AdenocarcinomaVer. 2.2014. Fort Washington, PA: nccn; 2014. [Current version available online at: http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf (free registration required); cited June 13, 2014]
11. Fleming JB. Borderline resectable pancreatic cancer. Presented at: The International Society of Gastrointestinal Oncology 2012 Gastrointestinal Oncology Conference; Arlington, VA, U.S.A.; September 13-15, 2012. [Available online at: http://www.isgio.org/isgio2012/abstracts/2012AbstractsS2A5.pdf; cited May 31, 2014]
12. Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009;16:1727-33.
13. Mollberg N, Rahbari NN, Koch M, et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg 2011;254:882-93.
14. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988;80:751-5.
15. Li CP, Chao Y, Chi KH, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 2003;57:98-104.
16. Willett CG, Del Castillo CF, Shih HA, et al. Long-term results of intraoperative electron beam irradiation (ioert) for patients with unresectable pancreatic cancer. Ann Surg 2005;241:295-9.
17. Heinrich S, Pestalozzi BC, Schafer M, et al. Prospective phase ii trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:2526-31.
18. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3496-502.
19. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3487-95.
20. Pisters PW, Wolff RA, Janjan NA, et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 2002;20:2537-44.
21. Artinyan A, Anaya DA, McKenzie S, Ellenhorn JD, Kim J. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer 2011;117:2044-9.
22. Miura JT, Krepline AN, Duelge KD, et al. Neoadjuvant therapy for pancreatic cancer in patients older than age 75 [abstract 287]. J Clin Oncol 2014;32(suppl 3):. [Available online at: http://meetinglibrary.asco.org/content/122914-143; cited June 1, 2014]
23. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7:e1000267.
24. Assifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase ii trials. Surgery 2011;150:466-73.
25. Andriulli A, Festa V, Botteri E, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol 2012;19:1644-62.
26. Greer SE, Pipas JM, Sutton JE, et al. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. J Am Coll Surg 2008;206:451-7.
27. Le Scodan R, Mornex F, Girard N, et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the sfro-ffcd 9704 trial and literature review. Ann Oncol 2009;20:1387-96.
28. Massucco P, Capussotti L, Magnino A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol 2006;13:1201-8.
29. Leone F, Gatti M, Massucco P, et al. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer 2013;119:277-84.
30. Rose JB, Rocha FG, Alseidi A, et al. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol 2014;21:1530-7.
31. Povoski SP, Karpeh MS Jr, Conlon KC, Blumgart LH, Brennan MF. Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy. Ann Surg 1999;230:131-42.
32. Faris JE, Blaszkowsky LS, McDermott S, et al. folfirinox in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist 2013;18:543-8.
33. Boone BA, Steve J, Krasinskas AM, et al. Outcomes with folfirinox for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol 2013;108:236-41.
34. Christians KK, Tsai S, Mahmoud A, et al. Neoadjuvant folfirinox for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist 2014;19:266-74.
35. Hattori M, Fujii T, Suenaga M, et al. Neoadjuvant chemoradiotherapy with S-1 in patients with borderline resectable pancreatic cancer [abstract 302]. J Clin Oncol 2014;32(suppl 3):. [Available online at: http://meetinglibrary.asco.org/content/122487-143; cited June 1, 2014]
36. Minter RM, Feng MUS, Al-Hawary K, et al. Effect of neoadjuvant chemoradiotherapy (ncrt) on survival in patients with borderline resectable (br) pancreatic adenocarcinoma (pda) with acceptable peri-operative morbidity [abstract 288]. J Clin Oncol 2014;32(suppl 3):. [Available online at: http://meetinglibrary.asco.org/content/122908-143; cited June 1, 2014]
37. Ansari D, Rosendahl A, Elebro J, Andersson R. Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg 2011;98:1041-55.
38. Schultz NA, Roslind A, Christensen IJ, et al. KRAS mutations and relation to prognosis in patients operated for localized pancreatic cancer and other periampullary cancers [abstract e15618]. J Clin Oncol 2009;27:. [Available online at: http://meeting.ascopubs.org/cgi/content/abstract/27/15S/e15618; cited June 1, 2014]
39. Oshima M, Okano K, Muraki S, et al. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg 2013;258:336-46.
40. de Albuquerque A, Kubisch I, Stolzel U, et al. Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients. J Transl Med 2012;10:222.
41. Ankeny JS, Hou S, Lin M, et al. Pancreatic circulating tumor cells as a diagnostic adjunct in pancreatic cancer [abstract 175]. J Clin Oncol 2014;32(suppl 3):. [Available online at: http://meeting.ascopubs.org/cgi/content/short/32/3_suppl/175?rss=1; cited June 1, 2014]
42. Jamieson NB, Carter CR, McKay CJ, Oien KA. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res 2011;17:3316-31.
43. Xu X, Strimpakos AS, Saif MW. Biomarkers and pharmacogenetics in pancreatic cancer. Highlights from the "2011 asco Annual Meeting." Chicago, IL, USA; June 3-7, 2011. JOP 2011;12:325-9.
44. Tsai S, Ritch PS, Erickson B, et al. Phase ii clinical trial of biomarker-directed therapy for localized pancreatic cancer [abstract TPS4147]. J Clin Oncol 2013;31:. [Available online at: http://meetinglibrary.asco.org/content/114020-132; cited June 1, 2014]
45. Perysinakis I, Avlonitis S, Georgiadou D, Tsipras H, Margaris I. Five-year actual survival after pancreatoduodenectomy for pancreatic head cancer. ANZ J Surg 2013;:[Epub ahead of print].
46. Hosein PJ, Macintyre J, Kawamura C, et al. A retrospective study of neoadjuvant folfirinox in unresectable or borderlineresectable locally advanced pancreatic adenocarcinoma. BMC Cancer 2012;12:199.
47. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008;206:833-46.